Market Summary
USD95.79+0.06
Market Closed0.06%
ABT Alerts
ABT Stock Price
ABT RSI Chart
ABT Valuation
ABT Price/Sales (Trailing)
ABT Profitability
ABT Fundamentals
ABT Revenue
ABT Earnings
Price Action
52 Week Range
93.25115.83
(Low)(High)
Last 7 days
-1.8%
Last 30 days
-6.9%
Last 90 days
-10.7%
Trailing 12 Months
-0.6%
ABT Financial Health
ABT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ABT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-13 | Funck, Jr. Robert E. | gifted | - | - | -20,000 | executive vice president |
2023-09-13 | Funck, Jr. Robert E. | gifted | - | - | 10,000 | executive vice president |
2023-09-01 | MCCOY JOHN A. JR. | acquired | - | - | 531 | vice president |
2023-09-01 | Boudreau Philip P | acquired | - | - | 2,620 | senior vice president |
2023-08-08 | Wainer Andrea F | acquired | 192,000 | 38.4 | 5,000 | executive vice president |
2023-08-08 | Wainer Andrea F | sold | -1,092,300 | 105 | -10,400 | executive vice president |
2023-07-27 | STARKS DANIEL J | sold | -5,688,190 | 113 | -50,000 | - |
2023-07-01 | Morrone Louis H. | sold (taxes) | -60,615 | 109 | -556 | executive vice president |
2023-06-30 | Morrone Louis H. | acquired | - | - | 1,815 | executive vice president |
2023-06-16 | Boudreau Philip P | sold | -848,000 | 106 | -8,000 | vice president |
Which funds bought or sold ABT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-10-02 | PARK NATIONAL CORP /OH/ | reduced | -2.12 | -5,384,340 | 35,893,600 | 1.62% |
2023-09-26 | M Holdings Securities, Inc. | sold off | -100 | -716,000 | - | -% |
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -48.38 | -354,716 | 443,820 | -% |
2023-09-26 | DecisionPoint Financial, LLC | reduced | -50.82 | -2,906 | 3,271 | -% |
2023-09-21 | Jefferies Group LLC | added | 69.6 | 2,301,650 | 6,810,840 | 0.06% |
2023-09-21 | Baystate Wealth Management LLC | added | 5.53 | 75,094 | 626,750 | 0.05% |
2023-09-20 | BARCLAYS PLC | added | 145 | 217,115,000 | 349,401,000 | 0.22% |
2023-09-19 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -6.23 | 24,845 | 2,625,200 | 1.10% |
2023-09-18 | CAPE ANN SAVINGS BANK | new | - | 284,324 | 284,324 | 0.19% |
2023-09-14 | IMS Capital Management | unchanged | - | 83,629 | 1,174,730 | 0.65% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
ABT Alerts
Schedule 13G FIlings of Abbott Laboratories
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 8.92% | 155,480,794 | SC 13G/A | |
| Feb 06, 2023 | blackrock inc. | 8.0% | 139,526,216 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 8.43% | 149,152,264 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.8% | 137,155,602 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 4.9% | 86,394,199 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.31% | 147,272,920 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.5% | 133,426,810 | SC 13G/A | |
| Feb 14, 2020 | capital research global investors | 6.4% | 113,689,293 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 8.58% | 151,783,436 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 7.1% | 124,728,602 | SC 13G/A |
Recent SEC filings of Abbott Laboratories
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 15, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 3 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 8-K/A | Current Report | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 03, 2023 | 10-Q | Quarterly Report | |
| Jul 28, 2023 | 4 | Insider Trading | |
| Jul 27, 2023 | 144 | Notice of Insider Sale Intent |
ABT Fair Value
Loading...
Peers (Alternatives to Abbott Laboratories)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABT | 166.7B | 40.2B | -6.92% | -0.60% | 32.3 | 4.14 | -11.68% | -39.67% |
DHR | 159.2B | 30.4B | -19.52% | -17.25% | 25.04 | 5.25 | -1.49% | 0.14% |
MDT | 101.8B | 31.6B | -5.31% | -3.69% | 28.08 | 3.23 | 1.57% | -30.40% |
ISRG | 101.2B | 6.7B | -4.97% | 57.37% | 71.01 | 15.18 | 11.75% | -0.66% |
IDXX | 35.3B | 3.5B | -15.71% | 32.27% | 44.63 | 10.05 | 6.21% | 19.20% |
| MID-CAP | ||||||||
PEN | 8.9B | 937.8M | -9.65% | 25.86% | 306.13 | 9.51 | 16.30% | 250.21% |
NEOG | 3.8B | 822.4M | -24.30% | 26.41% | -165.38 | 4.6 | 56.01% | -147.34% |
QDEL | - | - | -13.06% | 1.72% | - | - | - | - |
| SMALL-CAP | ||||||||
HSKA | 1.2B | 254.9M | 2.45% | 31.18% | -62.25 | 4.89 | -1.22% | 15.74% |
CYRX | 628.1M | 240.7M | -7.40% | -46.06% | -14.72 | 2.61 | 4.82% | 85.44% |
SRDX | 433.8M | 130.6M | -14.72% | 1.55% | -18.89 | 3.32 | 33.36% | -414.87% |
APEN | 419.8M | 76.9M | 0.50% | 67.22% | -10.54 | 5.46 | 22.01% | -61.41% |
XTNT | 119.8M | 67.9M | -12.88% | 59.77% | -13.57 | 1.76 | 21.30% | -10.24% |
DARE | 40.3M | - | -30.99% | -53.10% | -1.01 | 7.15 | 380.77% | -31.71% |
Abbott Laboratories News
Returns for ABT
Cumulative Returns on ABT
13.0%
10-Year Cumulative Returns
14.1%
7-Year Cumulative Returns
7.3%
5-Year Cumulative Returns
-2.3%
3-Year Cumulative Returns
Risks for ABT
What is the probability of a big loss on ABT?
36.5%
Probability that Abbott Laboratories stock will be more than 20% underwater in next one year
5%
Probability that Abbott Laboratories stock will be more than 30% underwater in next one year.
0%
Probability that Abbott Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ABT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Abbott Laboratories was unfortunately bought at previous high price.
Drawdowns
Financials for Abbott Laboratories
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -3.1% | 40,226 | 41,505 | 43,653 | 45,030 | 45,548 | 44,514 | 43,075 | 42,308 | 40,233 | 37,338 | 34,608 | 32,221 | 31,444 | 32,095 | 31,904 | 31,355 | 30,935 | 30,723 | 30,578 | 30,402 | 29,575 |
| Costs and Expenses | -1.3% | 34,101 | 34,546 | 35,291 | 35,594 | 35,336 | 35,286 | 34,650 | 33,829 | 32,805 | 30,630 | 29,251 | 27,907 | 27,427 | 27,544 | 27,372 | 27,047 | 26,830 | 26,942 | 26,928 | 27,266 | 26,665 |
| S&GA Expenses | -0.2% | 11,206 | 11,223 | 11,248 | 11,323 | 11,359 | 11,328 | 11,324 | 10,846 | 10,381 | 9,931 | 9,696 | 9,539 | 9,677 | 9,835 | 9,765 | 9,711 | 9,648 | 9,680 | 9,744 | 9,862 | 9,600 |
| R&D Expenses | 1.1% | 2,876 | 2,845 | 2,888 | 2,925 | 2,815 | 2,785 | 2,742 | 2,678 | 2,586 | 2,496 | 2,420 | 2,317 | 2,333 | 2,346 | 2,440 | 2,407 | 2,385 | 2,383 | 2,300 | 2,317 | 2,328 |
| EBITDA | -100.0% | - | 8,830 | 10,118 | 11,160 | 11,897 | 10,950 | 10,235 | 10,290 | 9,193 | 6,920 | 5,514 | 4,394 | 4,106 | 4,716 | 4,747 | 4,476 | 4,127 | 3,844 | 3,699 | 3,386 | 3,309 |
| EBITDA Margin | -100.0% | - | 0.21* | 0.23* | 0.25* | 0.26* | 0.25* | 0.24* | 0.24* | 0.23* | 0.19* | 0.16* | 0.14* | 0.13* | 0.15* | 0.15* | 0.14* | 0.13* | 0.13* | 0.12* | 0.11* | 0.11* |
| Interest Expenses | 4.7% | 607 | 580 | 558 | 535 | 527 | 529 | 533 | 538 | 542 | 542 | 546 | 574 | 604 | 638 | 670 | 692 | 728 | 770 | 826 | 886 | 901 |
| Earnings Before Taxes | -10.2% | 6,276 | 6,992 | 8,306 | 9,313 | 10,048 | 9,044 | 8,211 | 8,272 | 7,200 | 6,378 | 4,968 | 3,820 | 3,502 | 4,078 | 4,077 | 3,784 | 3,399 | 3,074 | 2,873 | 2,500 | 2,408 |
| EBT Margin | -100.0% | - | 0.17* | 0.19* | 0.21* | 0.22* | 0.20* | 0.19* | 0.20* | 0.18* | 0.17* | 0.14* | 0.12* | 0.11* | 0.13* | 0.13* | 0.12* | 0.11* | 0.10* | 0.09* | 0.08* | 0.08* |
| Net Income | -11.1% | 5,161 | 5,804 | 6,933 | 7,889 | 8,554 | 7,725 | 7,071 | 7,244 | 6,376 | 5,724 | 4,495 | 3,382 | 3,110 | 3,579 | 3,687 | 3,292 | 2,895 | 2,622 | 2,368 | 886 | 926 |
| Net Income Margin | -100.0% | - | 0.14* | 0.16* | 0.18* | 0.19* | 0.17* | 0.16* | 0.17* | 0.16* | 0.15* | 0.13* | 0.10* | 0.10* | 0.11* | 0.12* | 0.10* | 0.09* | 0.09* | 0.08* | 0.03* | 0.03* |
| Free Cashflow | -100.0% | - | 6,823 | 7,804 | 8,541 | 8,468 | 8,152 | 8,648 | 9,314 | 8,644 | 7,609 | 5,724 | 4,587 | 4,564 | 4,476 | 4,498 | 3,814 | 4,096 | 4,450 | 4,906 | 4,903 | 4,816 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -0.6% | 73,354 | 73,794 | 74,438 | 72,801 | 74,202 | 74,007 | 75,196 | 73,795 | 73,269 | 72,785 | 72,548 | 69,043 | 68,776 | 66,777 | 67,887 | 68,539 | 68,427 | 67,610 | 67,173 | 71,637 | 68,415 |
| Current Assets | -3.6% | 23,505 | 24,377 | 25,224 | 24,845 | 24,956 | 23,429 | 24,239 | 23,492 | 22,627 | 21,817 | 20,441 | 17,390 | 17,221 | 15,498 | 15,667 | 16,119 | 15,195 | 14,409 | 14,632 | 18,196 | 14,122 |
| Cash Equivalents | -14.5% | 7,835 | 9,161 | 9,882 | 9,594 | 8,937 | 7,675 | 9,799 | 9,302 | 8,658 | 8,054 | 6,838 | 4,480 | 4,763 | 3,377 | 3,860 | 4,091 | 3,137 | 3,022 | 3,844 | 7,369 | 3,065 |
| Inventory | 3.0% | 6,871 | 6,673 | 6,173 | 5,734 | 5,899 | 5,691 | 5,157 | 5,261 | 5,439 | 5,387 | 5,012 | 5,152 | 5,202 | 4,568 | 4,316 | 4,392 | 4,352 | 4,085 | 3,796 | 3,781 | 3,714 |
| Net PPE | 1.8% | 9,449 | 9,282 | 9,162 | 8,689 | 8,818 | 8,908 | 8,959 | 8,831 | 8,816 | 8,832 | 9,029 | 8,620 | 8,343 | 7,907 | 8,038 | 7,825 | 7,825 | 7,626 | 7,563 | 7,448 | 7,432 |
| Goodwill | 1.6% | 23,258 | 22,900 | 22,800 | 22,284 | 22,700 | 23,200 | 23,231 | 23,299 | 23,485 | 23,384 | 23,700 | 23,300 | 23,082 | 22,900 | 23,195 | 23,000 | 23,300 | 23,209 | 23,254 | 23,416 | 23,844 |
| Current Liabilities | -1.2% | 14,350 | 14,530 | 15,489 | 13,365 | 12,392 | 12,647 | 13,105 | 12,867 | 12,614 | 12,462 | 11,907 | 10,257 | 10,959 | 10,808 | 10,863 | 10,491 | 9,062 | 9,113 | 9,012 | 12,776 | 8,951 |
| Short Term Borrowings | - | - | - | - | - | - | - | - | 197 | 199 | 199 | 213 | 208 | 205 | 204 | 201 | 204 | 204 | 201 | 200 | 211 | 341 |
| LT Debt, Current | 0.0% | 2,284 | 2,285 | 2,251 | 1,117 | 5.00 | 4.00 | 754 | 754 | 755 | 756 | 7.00 | 6.00 | 1,290 | 1,264 | 1,277 | 1,254 | 8.00 | 8.00 | 7.00 | 4,063 | 506 |
| LT Debt, Non Current | -0.4% | 14,562 | 14,615 | 14,522 | 15,297 | 16,755 | 17,086 | 17,296 | 17,446 | 17,547 | 17,489 | 18,527 | 18,349 | 18,184 | 16,804 | 16,661 | 17,639 | 18,982 | 18,845 | 19,359 | 19,284 | 19,823 |
| Shareholder's Equity | 0.4% | 37,174 | 37,010 | 36,686 | 35,675 | 36,490 | 35,399 | 35,802 | 34,422 | 33,800 | 33,562 | 32,784 | 31,386 | 30,578 | 30,218 | 31,088 | 31,817 | 31,686 | 30,925 | 30,524 | 30,705 | 30,577 |
| Retained Earnings | 1.4% | 36,355 | 35,868 | 35,257 | 35,115 | 34,487 | 33,295 | 31,528 | 30,376 | 29,053 | 28,669 | 27,627 | 26,266 | 25,669 | 25,786 | 25,847 | 25,440 | 25,045 | 24,613 | 24,560 | 24,144 | 24,080 |
| Accumulated Depreciation | 1.4% | 11,477 | 11,323 | 11,050 | 10,617 | 10,640 | 10,613 | 10,405 | 10,351 | 10,258 | 9,865 | 9,764 | 9,352 | 9,031 | 8,800 | 8,761 | 8,518 | 8,506 | 8,279 | 8,143 | 8,072 | 7,877 |
| Shares Outstanding | -0.1% | 1,740 | 1,742 | - | 1,753 | 1,754 | 1,762 | - | 1,775 | 1,779 | 1,777 | - | 1,774 | 1,773 | 1,769 | - | 1,772 | 1,769 | 1,763 | - | 1,760 | 1,758 |
| Minority Interest | 3.6% | 230 | 222 | 219 | 209 | 226 | 230 | 222 | 216 | 229 | 226 | 219 | 209 | 220 | 209 | 213 | 202 | 208 | 204 | 198 | 193 | 197 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -13.9% | 7,452 | 8,659 | 9,581 | 10,322 | 10,243 | 9,961 | 10,533 | 11,264 | 10,629 | 9,823 | 7,901 | 6,519 | 6,401 | 6,139 | 6,136 | 5,485 | 5,720 | 5,904 | 6,300 | 6,175 | 5,997 |
| Share Based Compensation | -1.5% | 651 | 661 | 685 | 676 | 667 | 657 | 640 | 632 | 618 | 601 | 546 | 533 | 527 | 526 | 519 | 515 | 504 | 491 | 477 | 464 | 456 |
| Cashflow From Investing | -51.5% | -2,791 | -1,842 | -1,740 | -1,779 | -1,946 | -1,946 | -2,008 | -2,068 | -1,889 | -2,244 | -2,215 | -1,973 | -1,933 | -1,812 | -1,815 | -1,822 | -1,713 | -1,514 | -1,356 | -4,012 | -3,995 |
| Cashflow From Financing | -9.1% | -5,699 | -5,223 | -7,636 | -8,065 | -7,899 | -8,350 | -5,494 | -4,395 | -4,933 | -3,011 | -2,779 | -4,177 | -2,775 | -3,882 | -4,289 | -6,880 | -3,896 | -5,078 | -10,391 | -5,727 | -8,584 |
| Dividend Payments | 1.8% | 3,429 | 3,367 | 3,309 | 3,284 | 3,259 | 3,234 | 3,202 | 3,045 | 2,883 | 2,722 | 2,560 | 2,487 | 2,417 | 2,343 | 2,270 | 2,197 | 2,122 | 2,048 | 1,974 | 1,943 | 1,912 |
| Buy Backs | 20.8% | 2,449 | 2,028 | 3,795 | 4,084 | 3,865 | 4,331 | 2,299 | 1,486 | 909 | 442 | 403 | 738 | 737 | 737 | 718 | 326 | 328 | 327 | 238 | 145 | 150 |
ABT Income Statement
2023-06-30Condensed Consolidated Statement of Earnings (Unaudited) - USD ($) shares in Thousands, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Net sales | $ 9,978 | $ 11,257 | $ 19,725 | $ 23,152 |
| Cost of products sold, excluding amortization of intangible assets | 4,483 | 4,933 | 8,814 | 9,920 |
| Amortization of intangible assets | 498 | 507 | 989 | 1,019 |
| Research and development | 715 | 684 | 1,369 | 1,381 |
| Selling, general and administrative | 2,740 | 2,757 | 5,502 | 5,544 |
| Total operating cost and expenses | 8,436 | 8,881 | 16,674 | 17,864 |
| Operating earnings | 1,542 | 2,376 | 3,051 | 5,288 |
| Interest expense | 159 | 132 | 312 | 263 |
| Interest (income) | (98) | (26) | (199) | (40) |
| Net foreign exchange (gain) loss | 21 | 0 | 27 | (3) |
| Other (income) expense, net | (176) | (82) | (287) | (160) |
| Earnings before taxes | 1,636 | 2,352 | 3,198 | 5,228 |
| Taxes on earnings | 261 | 334 | 505 | 763 |
| Net Earnings | $ 1,375 | $ 2,018 | $ 2,693 | $ 4,465 |
| Basic Earnings Per Common Share (in dollars per share) | $ 0.79 | $ 1.15 | $ 1.54 | $ 2.53 |
| Diluted Earnings Per Common Share (in dollars per share) | $ 0.78 | $ 1.14 | $ 1.53 | $ 2.51 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,740,359 | 1,753,865 | 1,741,051 | 1,757,858 |
| Dilutive Common Stock Options (in shares) | 9,889 | 11,598 | 9,933 | 12,115 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,750,248 | 1,765,463 | 1,750,984 | 1,769,973 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 5,474 | 5,419 | 5,474 | 2,655 |
ABT Balance Sheet
2023-06-30Condensed Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 7,835 | $ 9,882 |
| Short-term investments | 320 | 288 |
| Trade receivables, less allowances of $485 in 2023 and $500 in 2022 | 6,172 | 6,218 |
| Inventories: | ||
| Finished products | 4,004 | 3,805 |
| Work in process | 845 | 680 |
| Materials | 2,022 | 1,688 |
| Total inventories | 6,871 | 6,173 |
| Prepaid expenses and other receivables | 2,307 | 2,663 |
| Total Current Assets | 23,505 | 25,224 |
| Investments | 799 | 766 |
| Property and equipment, at cost | 20,926 | 20,212 |
| Less: accumulated depreciation and amortization | 11,477 | 11,050 |
| Net property and equipment | 9,449 | 9,162 |
| Intangible assets, net of amortization | 9,834 | 10,454 |
| Goodwill | 23,258 | 22,799 |
| Deferred income taxes and other assets | 6,509 | 6,033 |
| Total Assets | 73,354 | 74,438 |
| Current Liabilities: | ||
| Trade accounts payable | 4,211 | 4,607 |
| Salaries, wages and commissions | 1,362 | 1,556 |
| Other accrued liabilities | 5,334 | 5,845 |
| Dividends payable | 886 | 887 |
| Income taxes payable | 273 | 343 |
| Current portion of long-term debt | 2,284 | 2,251 |
| Total Current Liabilities | 14,350 | 15,489 |
| Long-term debt | 14,562 | 14,522 |
| Post-employment obligations, deferred income taxes and other long-term liabilities | 7,038 | 7,522 |
| Commitments and Contingencies | ||
| Shareholders’ Investment: | ||
| Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued | 0 | 0 |
| Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,181,491; 2022: 1,986,519,278 | 24,612 | 24,709 |
| Common shares held in treasury, at cost — Shares: 2023: 251,823,511; 2022: 248,724,257 | (15,722) | (15,229) |
| Earnings employed in the business | 36,355 | 35,257 |
| Accumulated other comprehensive income (loss) | (8,071) | (8,051) |
| Total Abbott Shareholders’ Investment | 37,174 | 36,686 |
| Noncontrolling Interests in Subsidiaries | 230 | 219 |
| Total Shareholders’ Investment | 37,404 | 36,905 |
| Total Liabilities and Shareholders' Investment | $ 73,354 | $ 74,438 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.